Quick Takeaways
- TANG CAPITAL MANAGEMENT LLC filed SCHEDULE 13G for Spyre Therapeutics, Inc. Common Stock, par value $0.0001 per share (SYRE).
- Disclosed ownership: 5.3%.
- Date of event: 24 Apr 2025.
Quoteable Key Fact
"TANG CAPITAL MANAGEMENT LLC disclosed 5.3% ownership in Spyre Therapeutics, Inc. Common Stock, par value $0.0001 per share (SYRE) on 24 Apr 2025."
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT, LLC | 5.3% | 3,200,000 | 0 | 3,200,000 | /s/ Kevin Tang | Manager | |
| KEVIN TANG | 5.3% | 3,200,000 | 0 | 3,200,000 | /s/ Kevin Tang | Self | |
| TANG CAPITAL PARTNERS, LP | 3% | 1,799,658 | 0 | 1,799,658 | /s/ Kevin Tang | Manager, Tang Capital Management, LLC, General Partner | |
| TANG CAPITAL PARTNERS INTERNATIONAL, LP | 2.3% | 1,400,342 | 0 | 1,400,342 | /s/ Kevin Tang | Manager, Tang Capital Management, LLC, General Partner | |
| TANG CAPITAL PARTNERS III, INC | 0% | 0 | 0 | 0 | /s/ Kevin Tang | Chief Executive Officer | |
| TANG CAPITAL PARTNERS IV, INC | 0% | 0 | 0 | 0 | /s/ Kevin Tang | Chief Executive Officer |